Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →This Cochrane review of six RCTs involving 397 males aged 12 to 75 years reports that prophylactic emicizumab, fitusiran, or concizumab generally reduced bleeding compared with on-demand therapy in congenital hemophilia A or B, while increasing non-serious adverse events and providing variable, lower-certainty quality-of-life benefits.
The supplied RCT evidence supports non-clotting factor prophylaxis as a means of reducing bleeds in hemophilia relative to on-demand treatment; any application to children under 12 years, comparison with current factor-based prophylaxis, or use in pediatric-oncology bleeding management is an unsupported inference from this record.
This narrative review summarizes current pediatric melanoma management, available evidence for checkpoint inhibitors and targeted therapies, and ongoing trials of CAR T cells, NK-cell infusions, Wnt/β-catenin inhibitors, and cancer vaccines.
The supplied record supports that adult-derived immunotherapies and targeted therapies are already being considered for pediatric melanoma and that several novel approaches are under clinical investigation; it is reasonable—but not demonstrated here—to hypothesize that molecularly stratified, pediatric-specific use of these therapies could improve efficacy or safety.
In adults with metastatic NSCLC controlled after 6 months of first-line nivolumab plus ipilimumab, this prematurely interrupted randomized phase III trial reported no apparent four-year survival harm from stopping treatment, alongside fewer severe treatment-related adverse events and delayed quality-of-life deterioration versus continuation.
The trial provides direct adult evidence that fixed-duration nivolumab–ipilimumab may reduce toxicity and quality-of-life burden without an evident survival penalty in selected patients with controlled NSCLC; whether response-adapted immunotherapy de-escalation could benefit pediatric or adolescent cancers is an untested inference.
This meta-analysis of 14 studies involving 12,665 children with ALL reports that dexamethasone improved event-free survival versus prednisone but was associated with greater toxicity, with no significant differences in remission, relapse, or mortality.
The reported evidence supports a dexamethasone-associated event-free survival advantage accompanied by increased infectious, neuropsychiatric, and musculoskeletal toxicity; it remains an inference requiring prospective testing that hybrid, alternating, or risk-adapted glucocorticoid strategies could preserve benefit while reducing harm.
This review discusses immune checkpoint inhibition, CAR T and CAR NK therapies, molecular subgrouping, proteomics, and liquid biopsy as emerging approaches for medulloblastoma while emphasizing resistance, target-antigen scarcity, heterogeneity, and treatment toxicities.
The supplied record reports that CAR-based therapies and immune checkpoint strategies are being studied in medulloblastoma and that CAR NK therapy may be less prone to some limitations; it is an inference—not demonstrated here—that subgroup-informed antigen selection, checkpoint modulation, and proteomic or liquid-biopsy monitoring could improve efficacy or safety.
This systematic review reports that pediatric chemotherapy protocols may improve survival in adults with rhabdomyosarcoma, while evidence for Ewing sarcoma and osteosarcoma is limited, and that adults generally receive lower chemotherapy exposure and experience different toxicity patterns than children.
The evidence supports an association between pediatric-protocol treatment and improved survival in one non-metastatic adult rhabdomyosarcoma cohort; inferentially, maintaining adequate chemotherapy exposure and including disease-specific agents could improve adult sarcoma outcomes, but this requires confirmation in prospective studies and careful toxicity assessment.
This retrospective international multicenter study reports that, among patients with unresectable hepatocellular carcinoma and Child-Pugh B cirrhosis, atezolizumab/bevacizumab was associated with longer survival than sorafenib and that ALBI grade 1/2 without extrahepatic metastasis identified a subgroup with better outcomes.
The record supports an association between preserved liver function, absence of extrahepatic metastasis, and better outcomes with first-line atezolizumab/bevacizumab; it remains an inference requiring prospective validation that selecting patients by these features and actively treating underlying liver disease will improve survival.
In a six-patient phase Ib case series of newly diagnosed pediatric ATRT, bortezomib was combined with chemotherapy without reported grade 3 or higher bortezomib-related toxicity, while four response-evaluable patients had two partial responses, one stable disease, and one progressive disease.
The record provides preliminary evidence that bortezomib can feasibly be added to intensive ATRT therapy; it remains an inference, not demonstrated efficacy, that proteasome inhibition improves tumor control or survival beyond chemotherapy, surgery, and radiation alone.
This narrative review synthesizes preclinical and translational evidence that fatty acid oxidation, amino acid metabolism, mitochondrial dynamics, oxidative phosphorylation, and the kynurenine–AHR axis support brain-tumor survival, resistance, and immune evasion and may provide combination-treatment targets.
The reviewed evidence suggests that inhibiting selected non-glycolytic metabolic dependencies may sensitize metabolically defined brain tumors to radiotherapy, immunotherapy, or other treatments; this remains an inferred therapeutic strategy requiring brain-penetrant agents, biomarkers, and prospective clinical validation.
In this adult phase 3 HCC trial, adding STRIDE immunotherapy and lenvatinib to TACE significantly improved progression-free survival versus TACE alone, but overall survival was not significantly improved at the reported cutoff and serious adverse events were more frequent with the triplet regimen.
Evidence: STRIDE plus lenvatinib plus TACE reduced the risk of progression or death relative to TACE in embolisation-eligible adult HCC (HR 0.70), while an overall-survival benefit remained unproven and toxicity increased. Inference: combining checkpoint blockade and anti-angiogenic therapy with embolisation might improve disease control, but applicability to pediatric liver cancers cannot be inferred from this adult-only record.
This retrospective single-center study of 102 pediatric patients with very-high-risk or high-risk rhabdomyosarcoma found no significant differences in remission duration or 2-year event-free survival among three maintenance approaches, reported no grade 3 or higher treatment-related adverse events, and associated PAX-FOXO1 fusion, CDK4 mutation, and TP53 mutation with unfavorable remission duration.
The evidence supports the feasibility and potential prognostic value of targeted-drug and oral-chemotherapy maintenance strategies, including longitudinal ctDNA monitoring; it remains an inference—not proof—that ctDNA-guided maintenance selection could improve outcomes, because the retrospective nonrandomized comparisons did not establish efficacy equivalence or clinical utility.
This six-center observational cohort reports the feasibility, treatment interruptions, severe toxicities, MRD response associations, transplantation uptake, and early survival of 106 children receiving blinatumomab for relapsed/refractory or MRD-positive B-ALL in India, Pakistan, and Vietnam.
The observed early survival and association between MRD negativity after cycle 1 and improved outcomes support blinatumomab as a potentially deliverable and therapeutically useful option in resource-constrained pediatric referral centers; however, whether implementation support or blinatumomab itself improves outcomes requires controlled studies with more complete and longer follow-up.
